Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Part of paid clinical trials in New York, New York.

Sponsor: Memorial Sloan Kettering Cancer Center
Study ID: NCT00436709
Status: Unknown

Conditions

Breast Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

bevacizumab — BIOLOGICAL
pegfilgrastim — BIOLOGICAL
cyclophosphamide — DRUG
doxorubicin hydrochloride — DRUG
paclitaxel albumin-stabilized nanoparticle formulation — DRUG
flow cytometry — OTHER
immunoenzyme technique — OTHER
immunologic technique — OTHER
laboratory biomarker analysis — OTHER
adjuvant therapy — PROCEDURE
immunoscintigraphy — PROCEDURE

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This clinical trial is studying the side effects and how well giving bevacizumab together with doxorubicin and cyclophosphamide followed by paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab works in treating patients who have undergone surgery for early-stage breast cancer.